|
Press Releases |
|
![](/images/company/ShanghaiPharma_Article.jpg) |
|
Wednesday, August 27, 2014 |
|
上海醫藥2014年中期收入及利潤實現兩位數增長 |
中國醫藥產品製造及分銷市場領先的一體化醫藥公司 - 上海醫藥集團股份有限公司 (「上海醫藥」或「公司」,連同其附屬公司「集團」,股份代號:601607.SH;2607.HK),今天發佈2014年中期報告,報告顯示,2014年上半年,公司實現營業收入人民幣440.13億元,同比增長13.68%。 more info >> |
|
Shanghai Pharmaceuticals Achieves Double-Digit Growth of Revenue and Profit for 1H2014 |
Shanghai Pharmaceuticals Holding Co., Ltd. ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group; stock code: 601607.SH; 2607.HK), the integrated pharmaceutical company in the PRC that has leading positions in both pharmaceutical product and distribution markets more info >> |
|
Monday, March 31, 2014 |
|
上海医药2013年业绩 |
上海医药集团股份有限公司2013年公司实现营业收入为人民币782.23亿元,同比增长14.90%。实现归属于上市公司股东净利润为人民币22.43亿元,同比增长9.26%,扣除非经常性损益后增速达到15.16%。 more info >> |
|
上海醫藥2013年業績 |
上海醫藥集團股份有限公司2013年公司實現營業收入為人民幣782.23億元,同比增長14.90%。實現歸屬於上市公司股東淨利潤為人民幣22.43億元,同比增長9.26%,扣除非經常性損益後增速達到15.16%。
more info >> |
|
Shanghai Pharmaceuticals 2013 Annual Results |
Shanghai Pharmaceuticals Holding Co. Ltd. recorded operating revenue of RMB78.223 billion, up by 14.90% on a YOY basis. Net profit attributable to the equity holders of the listed Company was RMB2.243 billion, up by 9.26% on a YOY basis, and reached a growth of 15.16% after deducting non-recurring profit or loss. more info >> |
|
Wednesday, March 27, 2013 |
|
上药2012年净利润为人民币20.53亿元 |
上海医药于2012年录得理想业务表现,收入增加24%至680.78亿人民币,属于上市公司股东净利润为人民币20.53亿元,在扣除广东天普生化医药股份有限公司一次性特殊收益、及H股上市募集资金汇兑净损失后,归属于上市公司股东净利润较上年同期增长达13.5%。 more info >> |
|
上藥2012年淨利潤為人民幣20.53億元 |
上海醫藥於2012年錄得理想業務表現,收入增加24%至680.78億人民幣,屬於上市公司股東淨利潤為人民幣20.53億元,在扣除廣東天普生化醫藥股份有限公司一次性特殊收益、及H股上市募集資金匯兌淨損失後,歸屬於上市公司股東淨利潤較上年同期增長達13.5%。 more info >> |
|
Wednesday, April 20, 2011 |
|
上海医药与辉瑞就潜在战略伙伴关系签署谅解备忘录 |
上海医药集团股份有限公司(上交所股票代号:601607)与辉瑞公司(纽交所股票代号:PFE)今天宣布签署一份谅解备忘录,以共同寻求在中国的潜在的业务机会。 more info >> |
|
上海醫藥與輝瑞就潛在戰略夥伴關係簽署諒解備忘錄 |
上海醫藥集團股份有限公司(上交所股票代號:601607)與輝瑞公司(紐交所股票代號:PFE)今天宣佈簽署一份諒解備忘錄,以共同尋求在中國的潛在的業務機會。 more info >> |
|
Pfizer and Shanghai Pharmaceutical Sign Memorandum of Understanding for Potential Strategic Partnership |
Shanghai Pharmaceutical Co. Ltd. (SHSE: 601607) and Pfizer Inc. (NYSE: PFE) today announced the signing of a memorandum of understanding (MOU) for the companies to jointly pursue potential business opportunities in China. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
中港澳最大香水品牌管理公司穎通控股申請在港上市
Jul 18, 2024 23:30 HKT/SGT
|
|
|
中港澳最大香水品牌管理公司颖通控股申请在港上市
Jul 18, 2024 23:25 HKT/SGT
|
|
|
圓幣科技加入香港金融管理局穩定幣發行人「沙盒」 成為穩定幣創新先驅
Jul 18, 2024 23:06 HKT/SGT
|
|
|
RD Technologies Joins the HKMA Stablecoin Issuer Sandbox
Jul 18, 2024 22:59 HKT/SGT
|
|
|
OWIS Students Win Big at 10th SASMO Competition
Jul 18, 2024 22:00: JST
|
|
|
OWIS Students Win Big at 10th SASMO Competition
Jul 18, 2024 21:00 HKT/SGT
|
|
|
Champion REIT holds first 'ESG Week'
Jul 18, 2024 20:14 JST
|
|
|
冠君產業信託首度舉辦「ESG週」
Jul 18, 2024 19:04 HKT/SGT
|
|
|
Dubai AI & Web3 Festival & Trescon Launch FutureTech World Cup to Support Global Start-ups
Jul 18, 2024 18:36: JST
|
|
|
TAU Intelligence collaborates with Jardine Matheson and Intel to pioneer resource-efficient AI solutions
Jul 18, 2024 17:30 HKT/SGT
|
|
|
Lexus LBX Adds a New High Performance Variant, the LBX "MORIZO RR"
Jul 18, 2024 17:25 JST
|
|
|
Malaysian CropLife & Public Health Association Calls for Action Against Illegal Pesticides
Jul 18, 2024 16:00 HKT/SGT
|
|
|
VitalLife and Bumrungrad International Hospital in Thailand Launch NEC's FonesVisuas Test: First Major Deployment Outside Japan, Revolutionizing Disease Risk Prediction
Jul 18, 2024 15:34 JST
|
|
|
LEXUS、LBXにハイパフォーマンスモデルLBX“MORIZO RR”を新規設定
Jul 18, 2024 13:30: JST
|
|
|
Honda、新型燃料電池自動車「CR-V e:FCEV」を発売
Jul 18, 2024 13:00: JST
|
|
|
|
More News >> |
|
|
|
|
|